All In MedTech

Device Trial Radar · NCT06921707

Pilot Trial for WounDx Clinical Decision Support Tool

SC2i-WounDx-001-WounDx Pilot Trial: Proof of Concept Feasibility for the Clinical Operations of WounDx in Aiding Clinicians Identify Wounds That Are Ready For Surgical Closure

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

40

Planned (sponsor's estimate)

Start

May 1, 2026

Primary completion

Jun 30, 2027

Study completion Jun 30, 2027

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Duke University; University of Alabama at Birmingham; Brooke Army Medical Center; Grady Memorial Hospital; Indiana University Health; Uniformed Services University of the Health Sciences; Emory University
First posted
Apr 10, 2025

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Device feasibility
FDA-regulated device
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this research is to evaluate the overall use of the WounDx medical device in a clinical setting, such as a hospital. The WounDx device is experimental and not yet approved by the United States Food and Drug Administration (FDA). WounDx uses information about a patient's wound to generate a report that a surgeon may use to help determine when to close or not close the wound. The final decision to close the wound remains with the surgeon. The results from this pilot trial will inform a larger pivotal trial.

Conditions

  • Wounds
  • Wounds and Injuries
  • Extremity Injury
  • Traumatic Wounds and Injuries
  • Amputation, Traumatic/Surgery
  • Amputation, Wound
  • Open Fracture Wounds

Interventions

  • Clinical Decision Support ToolDevice

    WounDx is a clinical decision support tool that combines an immunoassay of six inflammatory biomarkers measured in wound effluent with wound characteristics to estimate the probability of successful wound closure. A probability of 0.85 or greater indicates a recommendation to close the wound at the next wound care procedure occurring 48-96 hours after the previous procedure. WounDx is applicable up to 21 days post-injury and augments the clinicians' judgment; the final closure decision remains with the clinician.

  • Standard of Care (SOC)Procedure

    The standard of care consists of negative pressure wound therapy and serial wound care procedures, including wound irrigation, surgical debridement, operative washout, and NPWT dressing changes.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Meeting Each Pilot Trial Operational Endpoint, by SiteTime frame: From enrollment through follow-up, 30-60 days after wound closure or 21 days post-injury, whichever occurs first (up to approximately 3 months)

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • University of Alabama - Birmingham Hospital

    Birmingham, Alabama · Recruiting

  • Emory University / Grady Memorial Hospital

    Atlanta, Georgia · Recruiting

  • Indiana University Health University Hospital

    Indianapolis, Indiana · Recruiting

2 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.